Background {#Sec1}
==========

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for first-line treatment of advanced NSCLC with sensitizing EGFR mutations \[[@CR1], [@CR2]\]. Despite high response rates of 60--70%, treatment failure inevitably ensues after a median duration of 10--18 months, regardless of choice of TKI. Although the emergence of genomic alterations commonly accounts for secondary resistance to EGFR TKI, CNS failure is often attributed to inadequate penetration into the CNS -- regarded as a 'sanctuary' site. Indeed, the lifetime risk of brain metastases (BM) is more than 30% of patients in EGFR mutant NSCLC, and where present, has traditionally been associated with poorer survival \[[@CR3]--[@CR5]\].

Although intracranial efficacy of first-line EGFR TKIs has not been established in prospective large-scale studies, clinical observations from trials support intracranial activity with afatinib -- a second-generation, irreversible pan-human epidermal growth factor receptor (HER) inhibitor. In a combined post-hoc analysis on patients with asymptomatic baseline BM from the LUX-lung 3 and LUX-lung 6 studies, afatinib significantly improved the objective response rate (RR) and progression-free survival (PFS) compared to chemotherapy \[[@CR3], [@CR6]\]. However, due to potent EGFR wild-type inhibition, afatinib is associated with increased skin and gastrointestinal toxicities, resulting in dose reductions reported in up to 53.3 and 28% patients in the randomized LUX-Lung 3 and 6 trials respectively \[[@CR7]\]. The potential impact of dose reductions with afatinib on CNS disease control also remains poorly characterized.

We performed a retrospective study to evaluate the clinicopathological factors affecting survival outcomes of patients with EGFRm+ NSCLC treated with first-line afatinib, specifically examining the impact of starting dose in patients with or without BM at diagnosis.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We retrospectively analyzed 125 consecutive patients with advanced/stage IV EGFRm+ NSCLC treated with first-line afatinib between January 2012 to February 2017 at the National Cancer Centre Singapore (NCCS) and consented to data collection for research purposes. We included eligible patients under our Lung Cancer Consortium Singapore (LCCS) data-base up to February 2017. Patients were analyzed for RR and PFS as per investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. After initiation of afatinib, radiological assessments of patients were performed at 2--3 month intervals as decided by the treating physician, with brain imaging by either contrasted computed tomography (CT) or magnetic resonance imaging (MRI) brain performed regularly for patients with documented brain metastases. An exploratory analysis was done for clinical factors that influenced survival. Reflex EGFR mutational analysis was performed by direct Sanger sequencing or Roche COBAS EGFR mutation test v2 \[[@CR8]--[@CR11]\]. This research was approved by our local Centralized Institutional Review Board (CIRB) and data was collected and subsequently analyzed anonymously prior to reporting.

Statistical analysis {#Sec4}
--------------------

PFS was defined as time from start of afatinib treatment to progression or death. Median PFS was estimated using the Kaplan-Meier method. Comparison of PFS between subgroups of patients was done using log-rank tests and Cox proportional hazards models. Two-sided *p*-values less than 0.05 were considered statistically significant. All analyses were performed in Stata (Version 14.2, StataCorp, Texas, USA).

Results {#Sec5}
=======

Clinico-pathologic characteristics {#Sec6}
----------------------------------

The baseline characteristics of the 125 patients with EGFRm+ lung cancer who received first-line afatinib are summarized in Table [1](#Tab1){ref-type="table"}. The median age at diagnosis was 62 years (range 26--86) and 121 (96.8%) had adenocarcinoma. 87 (69.6%) patients had EGFR exon 19 deletion, 27 (21.6%) had L858R mutation, and the rest (8.8%) had other EGFR mutations including G719A, E697Q, exon 20 mutations like A763_Y764insFQEA, double mutations or unknown. 95 (76.0%) patients were never-smokers and the remaining were former/current smokers. Of note, 42 (33.6%) patients had BM prior to afatinib initiation. 62 (49.6%) started on 40 mg once daily (OD) afatinib, 61 (48.8%) on 30 mg OD and 1 (0.8%) on 20 mg OD at the treating physician's discretion, due to concerns about drug tolerability.Table 1Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm+ NSCLC treated with first-line afatinib (*n* = 125) in our cohortCharacteristicNo.%Sex Male6451.2 Female6148.8Age at diagnosis, years Median62 Range26--86Ethnicity Chinese10080.0 Malay1411.2 Indian32.4 Others86.4Smoking status Never9576.0 Former1713.6 Current1310.4Histotype -- NSCLC Adenocarcinoma12196.8 Adenosquamous carcinoma10.8 NOS32.4EGFR mutation type Exon 19 deletion^\[a\]^8769.6 Exon 21 L858R2721.6 Others^\[b\]^118.8Brain metastases at baseline No8265.6 Yes4233.6 Unknown10.8Starting dose of afatinib once daily (OD) 40 mg6249.6 0 mg6148.8 0 mg10.8 Unknown10.8^\[a\]^E746_A750del; E746_A750delinsIP; E746_A750delinsQP; E746_A750delinsVP; E746_T751delinsV; E746_S752delinsV; E746_P753delinsVS; L747_A750delinsP; L747_T751del; L747_P753delinsS; NOS^\[b\]^E697Q; A763_Y764insFQEA; Double mutation; Unknown*NSCLC* Non-small cell lung cancer, *NOS* Not otherwise specified

Factors influencing outcomes to afatinib {#Sec7}
----------------------------------------

Median follow-up time was 13.8 months (95% CI 11.5 to 19.5 months) from start of afatinib treatment. Median duration of afatinib treatment was 8.7 months. At the time of data analysis in February 2017, 52 patients (41.6%) were still on afatinib. RR with afatinib was 70.4% and the disease control rate was 77.6%. No complete response (CR) was seen, while 11.2% had progressive disease (PD) as best overall RECIST response. The median PFS was 11.9 months (95% CI 10.3 to 19.3 months). Table [2](#Tab2){ref-type="table"} summarizes the clinical factors influencing PFS outcomes to afatinib in the total population by univariate analysis. Smoking history and EGFR mutation type were statistically significant clinical factors associated with PFS (log-rank *p* = 0.017 and \< 0.001, respectively). Interestingly, in patients with brain metastases, a lower starting dose was found to have a detrimental effect on outcomes.Table 2Factors influencing outcomes to afatinib. The clinical factors that influenced PFS in our cohortNo. of events/ patientsMedian PFS, months (95% CI)Log-rank *p*-valueHazard ratio (95% CI)Cox model *p*-valueTotal60 / 12011.9 (10.3, 19.3)NANANASex Male35 / 6213.3 (9.0, 20.1)0.34410.343 Female25 / 5811.9 (10.3, 25.7)0.78 (0.47, 1.31)Age at diagnosis, years  \< 6545 / 8611.9 (9.7, 19.3)0.79110.790  ≥ 6515 / 3411.7 (5.3, UD)0.92 (0.51, 1.66)Smoking history Never42 / 9114.5 (10.7, 22.1)0.01710.025 Former / Current18 / 297.9 (3.5, 17.4)1.94 (1.12, 3.38)EGFR mutation type Exon 19 deletion40 / 8315.0 (10.9, 22.1)\< 0.00110.008 L858R12 / 2711.2 (6.5, UD)1.19 (0.62, 2.28) Others6 / 84.5 (1.7, UD)5.51 (2.23, 13.64)Brain metastasis at start of afatinib No40 / 8015.0 (10.9, 20.6)0.14010.153 Yes20 / 407.9 (5.1, 13.3)1.50 (0.87, 2.57)^a^Starting dose^b^ 30 mg23 / 5810.7 (6.5, UD)0.10510.113 40 mg37 / 6115.0 (10.8, 20.6)0.63 (0.36, 1.11)Amongst patients with no brain metastasis:Starting dose^b^ 30 mg10 / 35UD0.89710.898 40 mg30 / 4415.0 (10.8, 22.1)0.95 (0.44, 2.04)Amongst patients with brain metastasis:Starting dose 30 mg13 / 235.3 (3.1, 10.7)0.04010.041 40 mg7 / 1713.3 (6.5, UD)0.39 (0.15, 0.99)Amongst patients on 30 mg starting dose:Brain metastasis No10 / 35UD0.00710.010 Yes13 / 235.3 (3.1, 10.7)2.96 (1.29, 6.79)Amongst patients on 40 mg starting dose:Brain metastasis No30 / 4415.0 (10.8, 22.1)0.56710.558 Yes7 / 1713.3 (6.5, UD)0.79 (0.34, 1.80)^a^*PFS* Progression-free survival, *NA* Not applicable, *UD* Undefined^a^Non-proportional hazards^b^One patient had a starting dose of 20 mg. This patient was excluded

Characteristics of patients with brain metastasis initiated on 30 mg vs. 40 mg {#Sec8}
------------------------------------------------------------------------------

We further analyzed the 42 patients with BM prior to afatinib initiation. 25 (59.5%) of them were started on 30 mg afatinib daily and 17 (40.5%) started on 40 mg. There were no significant differences between the 2 groups (40 mg vs 30 mg OD) for important clinical characteristics such as ECOG status, age and smoking history (Table [3](#Tab3){ref-type="table"}). There was greater proportion of females in the 30 mg group (*n* = 16/25, 64.0%) compared to 40 mg group (*n* = 6/11, 35.3%), but the difference was not statistically significant (*p* = 0.067). Of the 42 BM+ patients, 26 had upfront cranial irradiation due to symptomatic or multiple BM with mass effect. Patients who started on 40 mg were more likely to have undergone whole brain radiotherapy (WBRT) prior to afatinib compared to those started on 30 mg (*n* = 14/17, 82.4% vs *n* = 12/25, 48%, *p* = 0.024) for symptomatic BM (Table [3](#Tab3){ref-type="table"}). However, on further analysis to explore the effects of WBRT pre-afatinib, we found that starting dose remained significantly associated with PFS amongst patients who had cranial irradiation pre-afatinib, and in multivariable analysis adjusting for WBRT (Table [4](#Tab4){ref-type="table"}). At time of PD, most patients who started on 30 mg were still on the same dose (81.8%), whereas most of the 40 mg patients had dose reductions (70%) (Fig. [1](#Fig1){ref-type="fig"}).Table 3Comparison of characteristics between BM+ patients on 30 mg and 40 mg starting dose. Comparing the clinical characteristics of patients with brain metastases who started on 30 mg OD vs 40 mg OD of afatinibCharacteristicStarting dose 30 mg,\
n (%)Starting dose 40 mg,\
n (%)*p*-valueAge at diagnosis, years Median (range)62 (47--78)58 (26--76)0.299  \< 6515 (60.0)12 (70.6)0.482  ≥ 6510 (40.0)5 (29.4)Sex Female16 (64.0)6 (35.3)0.067 Male9 (36.0)11 (64.7)ECOG at start of afatinib 0--120 (80.0)14 (82.4)1.000 2--35 (20.0)3 (17.6)Smoking history Never18 (72.0)13 (76.5)1.000 Former/Current7 (28.0)4 (23.5)Brain RT pre-afatinib Yes12 (48.0)14 (82.4)0.024 No13 (52.0)3 (17.6)Brain RT post-afatinib Yes4 (16.0)3 (17.6)1.000 No21 (84.0)14 (82.4)EGFR mutation type Exon 19 deletion15 (62.5)9 (52.9)0.019 Exon 20 insertion1 (4.2)0 Exon 21 L858R3 (12.5)8 (47.1) Double mutation5 (20.8)0 Unknown10Site of progression^a^ CNS7 (63.6)3 (30.0)0.198 Systemic4 (36.4)7 (70.0) No PD / unknown:  Still on afatinib52  Went on 2nd line34  No scans / no PD recorded41  FU at other hospital20Afatinib dose at PD, mg 202 (18.2)1 (10.0)0.270 309 (81.8)6 (60.0) 4003 (30.0) No PD / unknown147Note: Unknown data were not included in the calculation of percentages and p-values^a^CNS PD: brain. Systemic PD: lung, bone/spine, liver, mediastinal LN, malignant pericardial effusion, nodes, pleura^b^Note that there were 9 patients (5 on 30 mg and 4 on 40 mg) who were still on afatinib at data cut-off. Dose intensity was calculated up to last follow-up date for these patientTable 4Multivariable model of afatinib starting dose and WBRT pre afatinib on PFS in BM+ patients at start of afatinib. The relationship between starting dose, WBRT pre-afatinib and PFS in patients with BM shown in a multivariable modelMultivariable analysisHazard ratio (95% CI)*p*-valueBrain RT pre-afatinib No1 Yes2.79 (0.93, 8.35)0.062Starting dose 30 mg1 40 mg0.22 (0.07, 0.67)0.006Fig. 1Swimmer plot on dose intensity of afatinib in BM+ patients. Individual swimmer plots for each patient with BM and started on 30 mg OD vs 40 mg OD afatinib, depicting duration and time of intracranial and extracranial disease progression (PD) on different doses of afatinib

Influence of starting dose on outcomes in patients with brain metastases {#Sec9}
------------------------------------------------------------------------

We next formally explored the interaction between BM and afatinib starting dose (Table [5](#Tab5){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). Amongst patients with BM, median PFS for those who received starting dose 40 mg OD vs. 30 mg OD was 13.3 vs. 5.3 months (HR 0.39, 95% CI 0.15--0.99) (Table [2](#Tab2){ref-type="table"}). However, for patients with no BM at start of afatinib, 40 mg starting dose had no significant impact on median PFS compared to 30 mg (HR 0.95, 95% CI 0.44--2.04). 21/42 BM+ patients had documented PD on afatinib and 1 patient (30 mg group) had both CNS and extracranial/systemic progression at time of PD. For site of first progression, patients who started on 40 mg were less likely to have CNS progression than those on 30 mg (30% vs 63.6%, *p* = 0.198) (Fig. [1](#Fig1){ref-type="fig"}), although this was not statistically significant due to the small numbers. Of note, patients with BM who started on 40 mg had similar PFS to patients with no BM (13.3 months vs. 15.0 months; HR 0.79, 95% CI 0.34--1.80). Similar results were obtained when this analysis was repeated in the subset of never-smokers with exon 19 deletions or L858R mutations (Table [5](#Tab5){ref-type="table"}).Table 5Interaction between brain metastasis and afatinib starting dose in PFS. The interaction effect of brain metastasis and starting dose of afatinib (40 mg vs 30 mg OD) in PFS of patients shown in a multivariable modelNo. of events / patientsHazard ratio\
(95% CI)*p*-valueBrain metastasis; starting dose60 / 119 Brain mets; 40 mg1 Brain mets; 30 mg3.73 (1.45, 9.61)0.006 No brain mets; 40 mg1.29 (0.57, 2.96)0.542 No brain mets; 30 mg1.21 (0.45, 3.23)0.711*p-value of brain mets-starting dose interaction:0.020*Amongst never smokers with exon 19 deletion or L858R mutation:Brain metastasis; starting dose37 / 84 Brain mets; 40 mg1 Brain mets; 30 mg5.23 (1.42, 19.28)0.013 No brain mets; 40 mg1.67 (0.57, 4.87)0.345 No brain mets; 30 mg1.10 (0.29, 4.20)0.884*p-value of brain mets-starting dose interaction:0.011*Fig. 2Kaplan-Meier (KM) plot of PFS showing the interaction between BM and starting dose of afatinib. KM plot showing interaction between presence of BM at start of treatment and starting dose of afatinib in our cohort

Discussion {#Sec10}
==========

In this retrospective analysis, we demonstrated clinical efficacy of afatinib in patients with EGFRm+ NSCLC consistent with large-scale randomized trials \[[@CR12], [@CR13]\], with worse outcome in patients with prior smoking histories. However, we did not identify the presence of BM as a negative prognostic factor, prompting us to further examine the patient characteristics and dosing profiles. Interestingly, we found that BM+ patients who commenced on afatinib 40 mg OD had better outcomes than those started on 30 mg OD (median PFS 5.3 vs 13.3 months, *p* = 0.041), and comparable to that of patients without BM (Fig. [2](#Fig2){ref-type="fig"}).

While first-line afatinib starting dose of 30 mg OD has been previously reported to have similar clinical efficacy as 40 mg OD and better tolerated in patients with EGFRm+ NSCLC \[[@CR14]\], the effect of starting dose on BM has not been studied. In the post-hoc analyses of LUX-Lung 3 and 6 trials reported by Yang and colleagues \[[@CR7]\], PFS of patients on afatinib reduced to 30 mg/day due to adverse events was found to be similar to those remaining on 40 mg/day. Although the authors concluded that dose adjustment of afatinib improved incidence of adverse events without compromising on therapeutic efficacy, such effect of afatinib dosing was not examined specifically in the subset of patients with brain metastases. Whereas in our study, we had demonstrated that significant effect of afatinib loading dose (40 mg vs 30 mg OD) on PFS was present only in patients with baseline brain metastases, and not amongst those without brain metastases prior to afatinib initiation -- a provocative finding suggesting afatinib dose effect on BM. To the best of our knowledge, this study is the first to demonstrate a difference on outcomes of BM+ patients with different starting doses of afatinib.

Conventionally, WBRT is considered the standard treatment for BM, especially for multiple and symptomatic BM. Although BM+ patients in the 40 mg group were more likely to have undergone WBRT prior to afatinib initiation as compared to the 30 mg group, it is noteworthy that starting dose remained significantly associated with PFS amongst patients who had WBRT before commencing afatinib, and also in multivariable analysis controlling for effect of WBRT. Moreover, patients who started on 40 mg tended to be less likely to progress intracranially than those on 30 mg dose, although not statistically significant due to small numbers. This effect was observed despite the frequency of dose reductions observed, and potentially represents how initial afatinib dose may impact on CNS control in these patients. This corroborates the findings of a competing risk analysis for progression of the LUX-Lung 3, 6, and 7 trials, that the hazard ratio for development of brain metastases as a site of progression was lower for afatinib compared to the control arms, providing another separate validation of the efficacy of afatinib as a brain-penetrant EGFR TKI \[[@CR15]\].

The benefit of dose of afatinib on CNS metastases may be driven by the peak plasma concentrations attained, with initial phase I studies showing significant difference in C~max~ (the maximum concentration of drug achieved after administration) when comparing 40 vs 30 mg \[[@CR16]\]. In a small case series, Hochmair et al. reported in patients with multiple, symptomatic BM who declined WBRT, afatinib alone could achieve complete intracranial remission \[[@CR17]\]. Two other studies also demonstrated effective CNS penetrance of afatinib -- a Japanese one with cerebrospinal fluid (CSF) pharmacokinetic data with first-line afatinib treatment \[[@CR18]\], and another German series demonstrating CNS activity in patients with BM progressing on first-generation TKIs \[[@CR6]\]. Additional studies directed at overcoming CNS treatment failure include high-dose gefitinib and erlotinib given in a pulsatile manner, highlighting the importance of C~max~ on intracranial responses \[[@CR19], [@CR20]\].

The main limitations of the current study include the small sample size and retrospective nature of the study, challenging the ability to draw definitive conclusions particularly with regards to afatinib dose effect on patterns of disease progression in BM+ patients. Notwithstanding this, our findings highlight the potential importance of C~max~ in control of brain metastases. This has significant implications on future studies in oncogene-driven NSCLC, where CNS metastases are a common reason for treatment failure and optimal CNS control remains an unmet need. A phase 1b study recently demonstrated the feasibility and tolerability of high-dose intermittent (HDI) afatinib (3 days every 14 days) achieving high plasma concentrations of afatinib, but focused on heavily pretreated advanced T790 M+ NSCLC \[[@CR21]\]. Albeit modest activity (7.7%) with HDI afatinib, this may be a potential strategy for patients with CNS metastases. To this end, we have initiated a prospective dose-finding study of continuous (40 mg OD) vs. intermittent high-dose (HDI) afatinib (160 mg × 3 days every 2 weeks) on CNS metastases and leptomeningeal disease in patients with advanced refractory EGFRm+ NSCLC (NCT03711422) to address control of CNS metastases. In this prospective study we will also be assessing the plasma and CSF drug ratios from the 2 different dosing schedules to determine pharmacokinetic efficacy of HDI afatinib on CNS control. Future prospective studies exploring alternative TKI dosing schedules such as intermittent dosing with 40 mg OD, so as to maintain C~max~ while circumventing toxicities from continuous dosing of afatinib, are warranted to specifically address the impact of drug exposure on durability of CNS disease control.

Conclusion {#Sec11}
==========

We demonstrated that in advanced EGFR-mutant NSCLC patients with brain metastases, starting dose of afatinib at 40 mg/day led to better clinical outcomes compared to those who had reduced starting dose of 30 mg/day, possibly due to effects of a higher C~max~ on CNS control. These results also lend support to the CNS activity from afatinib. Moving forward, further elucidation and validation of afatinib dose effect specifically on BM control with concomitant plasma C~max~ testing in a larger prospective study will certainly be crucial.
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